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Background and Aim 
     L-carnitine is an essential nutrient needed in fatty acid metabolism, that enables the 
translocation of long-chain fatty acids into the mitochondria. L-carnitine is actively 
transported via Organic Cation/Carnitine Transporter (OCTN)-2 into cells. In mammals, 
L-carnitine is usually obtained from dietary sources and biosynthesis in the body, and the 
skeletal muscle in the major tissue reservoir of L-carnitine. L-carnitine has been extensively 
used as a nutritional supplement in humans for losing body fat and/or avoiding muscle 
wasting. As well as in humans, metabolic problems in cats including obesity and wasting have 
been considered to be important health issues during recent decades. L-carnitine 
supplementation to obese cats has been frequently tried and was proved to accelerate body fat 
loss, however, there is still limited information about L-carnitine metabolism in cats. Recently, 
researchers have been focusing on the blood levels of L-carnitine to assess the relationship 
between L-carnitine metabolism and certain pathophysiological conditions. Serum L-carnitine 
concentrations elevate in human patients with hepatic cirrhosis, malignancy and chronic heart 
failure, and also in dogs with hepatic disorders. On the other hand, the significance of serum 
L-carnitine concentrations in cats is entirely unknown. The present study was designed to 
obtain basal information about L-carnitine levels in the feline serum, and to elucidate the 
underlying mechanisms those change the L-carnitine levels. Chapter I describes serum 
concentrations of total, free and acylated L-carnitine in the sera of clinically healthy cats and 
diseases cats. Chapter II deals with in vitro models of the skeletal muscle to simulate the 
release of L-carnitine from skeletal muscle cells under hypoxic or oxidative conditions. In 
Chapter III, a microarray technique was employed to analyze the gene expressions of murine 
skeletal muscle cells under hypoxic or oxidative stress in vitro to reveal the mechanism of 
L-carnitine release from cells. 
 
Chapter I: Serum L-carnitine levels in healthy and diseased cats 
     Firstly, serum total, free and acylated L-carnitine levels were measured in 41 clinically 
healthy cats at various ages by using commercial kits on an automatic biochemical analyzer. A 
positive correlation was found between the cats’ ages and the serum acylcarnitine levels, 
whereas serum total or free L-carnitine concentrations showed little age-related changes. 
Secondly, serum total, free and acylated L-carnitine levels were measured in 139 randomly 
selected feline patients with various diseases presented at the University of Tokyo Veterinary 
Medical Center between 2006 and 2012. Total and acylated L-carnitine concentrations were 
significantly higher in cats with diabetes mellitus, neoplastic disorders and cardiac disorders 
than those in healthy cats. Thirdly, relationships between serum L-carnitine levels and disease 
markers (serum amyloid A and haptoglobin as acute phase proteins; leptin as a marker of 
cachexia) were analyzed in the diseased cats. A weak but significant correlation between 
serum total L-carnitine and haptoglobin was confirmed. Thus, the increased serum L-carnitine, 
which might come from the skeletal muscle, was considered to reflect insulin resistance, 
inflammatory events and/or oxidative stress in cats with diabetes mellitus, malignancy and 
heart failure, respectively. Also, the data suggest the possibility of serum L-carnitine levels as 
a positive disease biomarker in cats. 
 
Chapter II: In vitro genetic analysis of L-carnitine release mechanism from murine 
skeletal myotubes under oxidative or hypoxic stress 
     To simulate the L-carnitine release from the skeletal muscle under oxidative and/or 
hypoxic conditions, in vitro models were employed. Mouse C2C12 myoblasts and 
commercially available primary cultures of feline skeletal myocytes were used for this aim. 
These cells were differentiated into myotubes and pre-cultured in culture media supplemented 
with 250 mM L-carnitine to construct the intracellular L-carnitine pools. The L-carnitine 
uptake was blocked by OCTN2 inhibitors (amiodarone, carvedilol, propantheline and 
verapamil), indicating the myotubes well presented OCTN2. After that, mouse and feline 
myotubes were cultured under an oxidative model (cells cultured in the presence of 0.5 mM 
H2O2 for 12 hours) or a hypoxic model (cells cultured under 100% nitrogen atmosphere for 12 
hours), and the intra- and extra-cellular L-carnitine amount was measured. Both in the 
oxidative and hypoxic models, release of L-carnitine into the extracellular space was 
accelerated. Additionally the OCTN2 inhibitors had no inhibitory effect on the L-carnitine 
release from the myotubes. In this Chapter, the disease-related release of L-carnitine from the 
skeletal muscle was reproduced at least in part in vitro, however, the efflux pathway of 
L-carnitine could not be identified. Intramyocellular L-carnitine might leak via passive 
permeability and/or unknown route. 
Chapter III: In vitro genetic analysis of L-carnitine release mechanism from murine 
skeletal myotubes under oxidative or hypoxic stress 
     To reveal the mechanism of L-carnitine release from murine C2C12 myotubes, a 
microarray technique was employed to analyze the gene expressions under the same oxidative 
or hypoxic conditions as in Chapter 2. Significant up-regulation of Mrpl52 and 
down-regulation of RNF220 were the major changes, indicating strong expression of 
mitochondrial transcript and suppression of the ubiquitin proteasome system, respectively. On 
the other hand, no significant changes in gene expression related to L-carnitine metabolism 
was observed. Despite the definite mechanism of intramyocellular L-carnitine release 
remained unclear, certain changes in mitochondrial function during energy loss might affect 
the maintenance of the L-carnitine pools. 
 
Conclusion 
     This study revealed the increase in feline serum L-carnitine level in diseased cats. The 
increased level was considered to reflect the L-carnitine release from the skeletal muscle 
accompanied by insulin resistance, inflammatory events and/or oxidative stress. The release 
of intramuscular L-carnitine under oxidative and/or hypoxic conditions may be via unknown 
pathways including passive permeability, and may be caused by muscular energy loss. 
     To date, L-carnitine has been supplemented to healthy and diseased cats with little 
evidence and little consideration. From the standpoint of this study, in diseased cats especially 
with diabetes mellitus, malignancy and heart failure, the serum L-carnitine level seems to be 
saturated by the release of L-carnitine from the skeletal muscle. To utilize L-carnitine for 
diseased cats, appropriate consideration about the L-carnitine metabolism would be needed. 
